Y-mAbs Therapeutics Inc. (YMAB)
Y-mAbs Therapeutics Statistics
Share Statistics
Y-mAbs Therapeutics has 45.22M shares outstanding. The number of shares has increased by 3.04% in one year.
Shares Outstanding | 45.22M |
Shares Change (YoY) | 3.04% |
Shares Change (QoQ) | 0.96% |
Owned by Institutions (%) | 64.43% |
Shares Floating | 34.45M |
Failed to Deliver (FTD) Shares | 3.28K |
FTD / Avg. Volume | 0.77% |
Short Selling Information
The latest short interest is 3.74M, so 8.35% of the outstanding shares have been sold short.
Short Interest | 3.74M |
Short % of Shares Out | 8.35% |
Short % of Float | 10.11% |
Short Ratio (days to cover) | 8.72 |
Valuation Ratios
The PE ratio is -11.7 and the forward PE ratio is -11.65. Y-mAbs Therapeutics's PEG ratio is -0.32.
PE Ratio | -11.7 |
Forward PE | -11.65 |
PS Ratio | 3.96 |
Forward PS | 1.7 |
PB Ratio | 3.77 |
P/FCF Ratio | -22.09 |
PEG Ratio | -0.32 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Y-mAbs Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.01.
Current Ratio | 4.16 |
Quick Ratio | 3.85 |
Debt / Equity | 0.01 |
Debt / EBITDA | -0.03 |
Debt / FCF | -0.05 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $843.13K |
Profits Per Employee | $-285.25K |
Employee Count | 104 |
Asset Turnover | 0.73 |
Inventory Turnover | 2.11 |
Taxes
Income Tax | -146K |
Effective Tax Rate | 0.49% |
Stock Price Statistics
The stock price has increased by -66.78% in the last 52 weeks. The beta is 0.65, so Y-mAbs Therapeutics's price volatility has been higher than the market average.
Beta | 0.65 |
52-Week Price Change | -66.78% |
50-Day Moving Average | 5.48 |
200-Day Moving Average | 10.34 |
Relative Strength Index (RSI) | 44.09 |
Average Volume (20 Days) | 426.7K |
Income Statement
In the last 12 months, Y-mAbs Therapeutics had revenue of 87.69M and earned -29.67M in profits. Earnings per share was -0.67.
Revenue | 87.69M |
Gross Profit | 72.43M |
Operating Income | -31.2M |
Net Income | -29.67M |
EBITDA | -31.2M |
EBIT | -31.2M |
Earnings Per Share (EPS) | -0.67 |
Balance Sheet
The company has 67.23M in cash and 820K in debt, giving a net cash position of 66.41M.
Cash & Cash Equivalents | 67.23M |
Total Debt | 820K |
Net Cash | 66.41M |
Retained Earnings | -487.14M |
Total Assets | 119.9M |
Working Capital | 74.81M |
Cash Flow
In the last 12 months, operating cash flow was -15.71M and capital expenditures 0, giving a free cash flow of -15.71M.
Operating Cash Flow | -15.71M |
Capital Expenditures | 0 |
Free Cash Flow | -15.71M |
FCF Per Share | -0.35 |
Margins
Gross margin is 82.61%, with operating and profit margins of -35.58% and -33.83%.
Gross Margin | 82.61% |
Operating Margin | -35.58% |
Pretax Margin | -34% |
Profit Margin | -33.83% |
EBITDA Margin | -35.58% |
EBIT Margin | -35.58% |
FCF Margin | -17.92% |
Dividends & Yields
YMAB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for YMAB is $20, which is 317.5% higher than the current price. The consensus rating is "Buy".
Price Target | $20 |
Price Target Difference | 317.5% |
Analyst Consensus | Buy |
Analyst Count | 11 |
Scores
Altman Z-Score | -0.72 |
Piotroski F-Score | 2 |